Non-Small Cell Lung Cancer and Tumor-Associated Macrophages: New Therapeutic Strategies

1. Concept

Lung cancer is the leading cause of cancer-related deaths globally, with non-small cell lung cancer (NSCLC) accounting for the majority of cases. Despite advances in comprehensive treatment strategies, the 5-year survival rate for NSCLC patients remains low. The tumor microenvironment (TME)—a complex network of cancer cells, immune cells, fibroblasts, endothelial cells, and extracellular matrix components—plays a pivotal role in tumor progression. Tumor-associated macrophages (TAMs), key immune regulators in the TME, exhibit high plasticity: they can adopt a tumor-promoting M2 phenotype or an anti-tumor M1 phenotype. This study identifies fibronectin (encoded by the FN1 gene) as a key regulatory molecule in TAMs. Fibronectin drives M2 polarization and immunosuppression in NSCLC, and targeting the fibronectin signaling pathway repolarizes TAMs to M1, enhancing anti-tumor immunity—offering a novel therapeutic strategy for NSCLC.

2. Research Frontiers

2.1 Background

• NSCLC burden: NSCLC is the most common lung cancer subtype, with limited treatment efficacy and poor prognosis, highlighting the need for novel therapeutic targets.
• TAM plasticity: TAMs are the most abundant immune cells in the NSCLC TME. M2 TAMs secrete immunosuppressive cytokines to promote tumor growth, invasion, and metastasis; M1 TAMs enhance anti-tumor immunity by secreting pro-inflammatory factors and activating cytotoxic T cells.
• FN1 gene and fibronectin: Fibronectin, encoded by the FN1 gene, is an extracellular matrix glycoprotein. Recent studies link it to tumor progression, but its role in TAM polarization and NSCLC immunoregulation remains unclear.

2.2 Research Methods

• Bioinformatics analysis: RNA-Seq data from the GEO database identified differential gene expression between M1 and M2 macrophages; single-cell sequencing analyzed FN1 expression in NSCLC cells.
• Flow cytometry: Detected fibronectin-positive cells and macrophage subpopulations (CD163+ M2, CD163- M1) in NSCLC tissues.
• Molecular biology assays: RNA-Seq and qPCR assessed FN1 expression in sorted CD163+ and CD163- macrophages.
• Functional validation: Fibronectin inhibitor (FI) was used to treat M2 macrophages; flow cytometry, Western blot, and imaging flow cytometry evaluated TAM phenotype and function.
• In vivo studies: C57BL/6J mice bearing LLC-luciferase subcutaneous tumors were used to assess the effects of fibronectin pathway blockade on tumor growth and immune cell profiles.

2.3 Key Research Results

• FN1 high expression in M2 TAMs: GEO and single-cell sequencing confirmed elevated FN1 expression in M2 macrophages within the NSCLC TME.
• Fibronectin inhibition induces M2-to-M1 repolarization: Treating M2 macrophages with FI promoted their conversion to M1, increasing secretion of pro-inflammatory cytokines.
• Mechanism of fibronectin-mediated immunosuppression:
• Fibronectin promotes F-actin aggregation in M2 macrophage cell membranes, facilitating autophagic degradation of PFKP (a key glycolytic enzyme) and suppressing glycolysis.
• Fibronectin and F-actin inhibit IL-1β expression via CEBPα, maintaining M2’s immunosuppressive function.
• In vivo efficacy: Blocking fibronectin signaling repolarized TAMs to M1, enhanced CD8+ T cell cytotoxicity, reduced TAM autophagy, and increased PFKP expression—significantly inhibiting tumor growth.

2.4 Conclusion

Fibronectin is highly expressed in M2 TAMs of NSCLC tissues. It drives immunosuppression by promoting F-actin aggregation, PFKP degradation, and IL-1β inhibition. Targeting the fibronectin pathway reverses TAM polarization, boosts anti-tumor immunity, and provides a promising therapeutic strategy for NSCLC. Future research should validate these mechanisms clinically and explore combination therapies to maximize efficacy.

3. Research Significance

This study uncovers the fibronectin-TAM regulatory axis in NSCLC, with profound scientific and clinical value:

• Scientific value: Elucidates the molecular mechanism by which fibronectin regulates TAM polarization, expanding understanding of TME immunoregulation and providing a new link between extracellular matrix and tumor immunity.
• Clinical value: Identifies fibronectin as a novel therapeutic target for NSCLC. TAM repolarization via fibronectin inhibition enhances anti-tumor immunity, offering a new approach to improve the efficacy of immunotherapy and chemotherapy for NSCLC patients.

4. Related Mechanisms, Research Methods, and Product Applications

4.1 Core Mechanism of Fibronectin-Mediated TAM Polarization

• Fibronectin binds to integrins on M2 TAMs, triggering intracellular signaling that promotes F-actin aggregation.
• F-actin aggregation induces autophagic degradation of PFKP, suppressing glycolysis and maintaining M2 metabolism.
• Simultaneously, fibronectin-F-actin signaling inhibits IL-1β expression via CEBPα, sustaining the immunosuppressive M2 phenotype.
• Blocking fibronectin disrupts this cascade, restoring PFKP expression, promoting glycolysis, and inducing M2-to-M1 repolarization.

4.2 Product Applications: ANT BIO PTE. LTD.’s Fibronectin-Related Products

ANT BIO PTE. LTD. offers high-quality fibronectin proteins, standards, and antibodies to support TAM polarization and NSCLC research:

Core Products

Key Application Scenarios

• Mechanism research: Recombinant fibronectin protein validates its effect on TAM polarization and glycolysis; antibodies detect fibronectin expression in TAMs and tumor tissues.
• Quantitative detection: Fibronectin standards support ELISA-based quantification of fibronectin levels in serum, tumor tissues, or cell supernatants.
• Drug screening: Evaluate the efficacy of fibronectin inhibitors in repolarizing TAMs and inhibiting tumor growth.

5. Brand Mission

ANT BIO PTE. LTD. is dedicated to empowering the global life science community with high-quality, innovative research tools and solutions. As a leader in life science reagents, we offer a comprehensive portfolio under three sub-brands: Absin (focused on general reagents and kits), Starter (specialized in antibodies), and UA (dedicated to recombinant proteins).

Our commitment to excellence is underpinned by advanced development platforms—including recombinant rabbit/mouse monoclonal antibody platforms, rapid monoclonal antibody development, recombinant protein expression systems (E. coli, CHO, HEK293, Insect Cells), One-Step ELISA Platforms, and PTM Pan-Modification Antibody Platforms—alongside rigorous quality control systems. We hold international certifications such as EU 98/79/EC, ISO9001, and ISO13485, ensuring our products meet the highest global standards.

Our mission is to accelerate scientific discovery, facilitate translational research, and contribute to the development of novel therapies for human health. By partnering with researchers in academia and biopharmaceutical companies worldwide, we strive to be a trusted collaborator in advancing life science research and addressing unmet medical needs.

6. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.